Drug intelligence / Profile preview

carboplatin + carmustine

Development stage: Preclinical
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Intra-arterial

Overview

Carboplatin + carmustine is a chemotherapy combination regimen consisting of two alkylating agents. This combination has been studied in the treatment of glioblastoma and potentially other malignancies. In clinical studies, this combination has shown promising results with patients treated with carboplatin-based regimens having significantly longer survival times compared to those treated with carmustine alone.

Targets

DNAGSR (Glutathione reductase)

Beyond the preview

Go deeper on carboplatin + carmustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + carmustine.

Explore the full profile